Tonix制药控股 TNXP 深 沪
已收盘 02-06 16:00:00 美东时间
16.34
+1.390
+9.30%
华盛通- 最 高16.345
- 今 开15.40
- 成交量 30.38万股
- 最 低 15.1101
- 昨 收 14.95
- 总市值 30.54亿
- 52周最高 69.97
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 6.76
- 委 比 37.36%
- 总股本 1.87亿
- 历史最高 13440000000.00
- 量 比 0.74
- 振 幅 8.26%
- 历史最低 14.93
- 每 手 1
- 风险率 11.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | Tonix制药控股2025财年年度营收0.13亿美元，同比增长29.7%；归母净利润亏损1.19亿美元，同比亏损缩窄8.5%
华盛资讯2月4日讯，Tonix制药控股公布2025财年年度业绩，公司年度营收0.13亿美元，同比增长29.7%，归母净利润亏损1.19亿美元，同比亏损缩窄8.5%。
02-04 00:04
Tonix Pharma Incorporates Prior Financial Information by Reference
Tonix Pharma ( ($TNXP) ) has issued an announcement. Tonix Pharma disclosed tha...
02-03 20:30
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
BUZZ-Tonix pain‑relief drug meets main goal in late‑stage study; shares fall
BUZZ-Tonix pain‑relief drug meets main goal in late‑stage study; shares fall ** Shares of drug developer Tonix Pharmaceuticals TNXP.O fall 1.6% to $17.93 premarket ** Co says its pain‑relief drug Tonmya met the main goal in a late‑stage study for Fibromyalgia, a chronic widespread pain condition **
01-30 21:25
Tonix Pharmaceuticals Presents Data On TONMYA, Which Was Investigated As TNX-102 SL, At 2026 Non-Opioid Pain Therapeutics Summit
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing
01-30 20:04
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
<p>Tonix Pharmaceuticals presented data showing TONMYA™ significantly reduced fibromyalgia pain compared to placebo in a Phase 3 study. The unique sublingual formulation bypasses first-pass metabolism, optimizing drug exposure during sleep and reducing metabolite levels. TONMYA was well-tolerated, with minimal effects on weight or blood pressure. It is the first new FDA-approved prescription treatment for fibromyalgia in over 15 years and targets...
01-30 12:00
Tonix Pharmaceuticals Showcases Pipeline Progress and Fibromyalgia Drug Launch in Investor Presentation
Tonix Pharmaceuticals Showcases Pipeline Progress and Fibromyalgia Drug Launch in Investor Presentation Tonix Pharmaceuticals Holding Corp. has released an investor presentation highlighting its current business operations and financial position. The company reports having three FDA-approved product
01-22 19:36
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Tonix Pharmaceuticals Holding Corp. announced its participation in upcoming investor conferences in January 2026, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, where CEO Seth Lederman will present. The company specializes in biotechnology with a focus on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases, including products such as TONMYA for f...
01-06 12:00
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-02 01:35
Tonix Pharma Announces $20 Million Registered Direct Offering
Tonix Pharma ( ($TNXP) ) just unveiled an announcement. On December 29, 2025, T...
2025-12-30 05:58
